News

Under the terms of the agreement, Lilly will fund a collaborative research and development program with the aim of creating improved drugs incorporating SPL’s proprietary delivery technology, and

The Establishment License issued by Health Canada will enable Dalton to continue to manufacture, test and ship sterile commercial products for its existing clients. In addition, Dalton’s solid

In accordance with the Scheme, all Scheme shares have been transferred to YM and Cytopia is now a wholly-owned subsidiary of YM. The Scheme Consideration, as well as

Bernardo Gradin, CEO of Braskem, said: “The acquisition of Sunoco Chemicals provides Braskem with a solid and competitive platform for growth in the world’s biggest market, which will

Luliconazole is a potent and broad-spectrum topical antifungal agent in development and will be advancing to phase 3 clinical development in the US for tinea pedis (athlete’s foot).

The open label, single centre pharmacokinetic study in 20 healthy volunteers was conducted at the Royal Adelaide Hospital. The primary objective of the study was to compare the

The exclusive license grants GCAT the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong

This facility is likely to provide on-site chemistry resources for Pfizer along with a resource for other developing companies in the vicinity. Tony Wood, vice president of world-wide

The prospective, observational study involved 321 patients with acute STEMI, without cardiogenic shock, who received 357 Genous stents. The rate of major adverse cardiac events (MACE) was 8.1%